# US 2026/0060979 A1 · Method for improving neuroplasticity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060979 A1
- Document ID: US20260060979A1
- Status: Published application
- Kind: A1
- Application number: 19/316,824
- Filed: 2025-09-02
- Published: 2026-03-05
- Earliest claimed: 2024-09-04
- Assignees: Alto Neuroscience, Inc.
- Applicants: Alto Neuroscience, Inc.
- Inventors: Amit Etkin; Adam Savitz; Akash Datwani; Maria Ferreira da Silva
- Web page: https://patentgrep.com/patent/US20260060979A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and/or memory) and/or certain EEG characteristics.

## Claims

### Claim 1

A method of treating major depressive disorder, post-traumatic stress disorder, or one or more symptoms thereof in a human patient having (a) objectively determined cognitive impairment or poor cognition, (b) objectively determined impaired learning and/or memory, (c) an electroencephalogram (EEG) exhibiting (i) a low aperiodic exponent, (ii) a high power in the low gamma range, (iii) a low power in the alpha frequency, (iv) low power at the centro-parietal electrodes in the theta frequencies, (v) low power at the centro-parietal electrodes in the alpha frequencies, (vi) low power at the frontal electrodes in the alpha frequencies, (vii) high aperiodic exponent at one or more posterior electrodes, or (viii) any combination of any of the foregoing, or (d) any combination of any of the foregoing, the method comprising administering to the patient an effective amount of a therapeutic agent, wherein the therapeutic agent is selected from (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a brain-derived neurotrophic factor (BDNF) receptor, e.g., a 5-HT2A agonist that binds to the tropomyosin receptor kinase B (TrkB) receptor or low-affinity nerve growth factor receptor (p75NTR)), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, and (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound).

### Claim 2 (depends on 1)

The method of claim 1, wherein the human patient suffers from cognitive impairment or poor cognition as shown by one or more of a simple reaction time test, choice reaction time test, one back working memory task, and visual learning task.

### Claim 3 (depends on 1)

The method of claim 1, wherein the human patient suffers from cognitive impairment or poor cognition as shown by a composite score which is at least partially based upon one or more results from a simple reaction time test, choice reaction time test, one back working memory task, or visual learning task.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient suffers from reduced attention, memory, learning, working memory, or any combination of any of the foregoing.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient suffers from major depressive disorder or one or more symptoms thereof and exhibits an electroencephalogram (EEG) with (i) a low aperiodic exponent, (ii) a high power in the low gamma range, (iii) a low power in the alpha frequency, or (iv) any combination of any of the foregoing.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient has objectively determined impaired verbal learning and/or memory.

### Claim 7 (depends on 1)

The method of claim 1, wherein the human patient suffers from impaired learning and/or memory as shown by VM-REACT (Verbal Memory REcAll Computerized Test), The Rey Auditory Verbal Learning Test, California Verbal Learning Test, California Verbal Learning Test—Short Form, California Verbal Learning Test—Children's Version, Hopkins Verbal Learning Test, Hopkins Verbal Learning Test—Revised, Philadelphia Verbal Learning Test, International Shopping List Test, Verbal section of the Repeatable Battery for the Assessment of Neuropsychological Status, Cerad Neuropsychological Assessment Battery Word List Task, Children's Auditory Verbal Learning Test, Children's Memory Scale, Bay Area Verbal Learning Test, Cogstate battery (which can include the following subtests: Behavioral Pattern Separation Object Test, Continuous Paired Associate Learning Test, Face Name Associative Memory Exam, Groton Maze Learning Test and its Delayed Recall and Delayed Reverse Recall versions, International Shopping List, One Card Learning Test), CANTAB (which can include the following subtests: Delayed Matching to Sample, Pattern Recognition Memory, Verbal Paired Associates, Paired Associates Learning, Verbal Recognition Memory), Penn Computerized Neurocognitive Battery (which can include the following subtests: Penn Word Memory Task, Penn Face Memory Task, Visual Object Learning Test), the NIH Toolbox and its subtests (Face Name Associative Memory Exam Test, Picture Sequence Memory Test, and Rey Auditory Verbal Learning Test), Neuropsychological Assessment Battery Memory Module, WHO/UCLA Auditory Verbal Learning Test, Repeatable Battery for the Assessment of Neuropsychological Status, Wide Range Assessment of Memory and Learning, Buschke Selective Reminding Test, Wechsler Memory Scale, Woodcock-Johnson Long Term Retrieval factor, Test of Memory and Learning, NEPSY, Brief Visuospatial Memory Test—Revised, Benton Visual Retention Test, Rey Osterreith Complex Figure Test, and any combination of any of the foregoing.

### Claim 8

(canceled)

### Claim 9

A method of treating major depressive disorder in a human patient having reduced information processing speed, attention, memory, learning, working memory, or any combination of any of the foregoing, comprising administering to the patient an effective amount of a therapeutic agent, wherein the therapeutic agent is selected from (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, and (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound).

### Claim 10 (depends on 1)

The method of claim 1, wherein the patient suffers from anhedonia, suicidality, or both.

### Claim 11 (depends on 1)

The method of claim 1, wherein the patient suffers from reduced information processing speed.

### Claim 12

A method of treating one or more symptoms selected from depressive symptoms, anhedonia, loss of interest, avolition, diminished emotional expression, inability to feel, amotivation, apathy, slow thinking, psychomotor retardation, lassitude, or any combination of any of the foregoing in a human patient suffering from post-traumatic stress disorder, bipolar depression, substance use disorder or schizophrenia, where the patient has (a) objectively determined cognitive impairment or poor cognition, (b) objectively determined impaired learning and/or memory, (c) an electroencephalogram (EEG) exhibiting (i) a low aperiodic exponent, (ii) a high power in the low gamma range, (iii) a low power in the alpha frequency, (iv) low power at the centro-parietal electrodes in the theta frequencies, (v) low power at the centro-parietal electrodes in the alpha frequencies, (vi) low power at the frontal electrodes in the alpha frequencies, (vii) high aperiodic exponent at one or more posterior electrodes, or (viii) any combination of any of the foregoing, or (d) any combination of any of the foregoing, the method comprising administering to the patient an effective amount of a therapeutic agent, wherein the therapeutic agent is selected from (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, and (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound).

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The method of claim 12, wherein the patient is concurrently treated with one or more antipsychotic medications, mood stabilizers, or any combination of any of the foregoing.

### Claim at position 15

15-34. (canceled)

### Claim 35 (depends on 1)

The method of claim 1, wherein the patient has impaired learning and/or memory as objectively determined by poor immediate recall in a verbal memory test.

### Claim 36 (depends on 1)

The method of claim 1, wherein the patient has impaired learning and/or memory as objectively determined by poor delayed recall in a verbal memory test.

### Claim 37 (depends on 1)

The method of claim 1, wherein the patient is not concurrently treated with a second antidepressant medication.

### Claim 38 (depends on 1)

The method of claim 1, wherein the patient is concurrently treated with a second antidepressant medication.

### Claim 39 (depends on 1)

The method of claim 1, wherein prior to treatment with the therapeutic agent, the patient had an insufficient response to an antidepressant other than the therapeutic agent.

### Claim 40 (depends on 1)

The method of claim 1, wherein the patient was, prior to treatment with the therapeutic agent, treated with one or more antidepressants and continues treatment with the one or more antidepressants during treatment with the therapeutic agent.

### Claim 41 (depends on 39)

The method of claim 39, wherein the one or more antidepressants do not include a monoamine oxidase inhibitor (MAOI) or a tricyclic antidepressant.

### Claim 42 (depends on 39)

The method of claim 39, wherein the one or more antidepressants are selected from serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, mirtazapine, bupropion, and any combination of any of the foregoing.

### Claim at position 24

43-52. (canceled)
